GlobeNewswire: Five Prime Therapeutics, Inc. Contains the last 10 of 182 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:40:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/02/13/1340210/0/en/Five-Prime-Therapeutics-to-Announce-Fourth-Quarter-and-Full-Year-2017-Financial-Results-and-Host-Conference-Call-on-February-27.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 272018-02-13T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, February 27, 2018, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.]]>https://www.globenewswire.com/news-release/2018/02/08/1336613/0/en/Five-Prime-Therapeutics-to-Present-at-LEERINK-Partners-7th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference2018-02-08T21:10:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the LEERINK Partners 7th Annual Global Healthcare Conference, Feb. 14, 2018, at 11:30 am ET.]]>https://www.globenewswire.com/news-release/2018/01/29/1313883/0/en/Five-Prime-Therapeutics-Announces-Closing-of-Upsized-Public-Offering.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics Announces Closing of Upsized Public Offering2018-01-29T21:05:00Z<![CDATA[Underwriters Fully Exercise Option to Purchase Additional Shares Underwriters Fully Exercise Option to Purchase Additional Shares]]>https://www.globenewswire.com/news-release/2018/01/25/1305271/0/en/Five-Prime-Therapeutics-Announces-25-Million-Payment-by-Bristol-Myers-Squibb-for-Cabiralizumab-Development-Milestone.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone2018-01-25T21:05:00Z<![CDATA[Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer]]>https://www.globenewswire.com/news-release/2018/01/25/1304916/0/en/Five-Prime-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=11636 Five Prime Announces Pricing of Upsized Public Offering of Common Stock2018-01-25T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), announced today the pricing of an underwritten public offering of 5,128,205 shares of its common stock at a price to the public of $19.50 per share. The size of the offering was upsized from $75 million to $100 million. Five Prime estimates that the net proceeds from the sale of the shares will be approximately $93.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Five Prime. In addition, Five Prime has granted the underwriters in the offering a 30-day option to purchase up to 769,230 additional shares of common stock at the public offering price. The offering is expected to close on January 29, 2018, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2018/01/23/1299420/0/en/Five-Prime-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=11636Five Prime Announces Proposed Public Offering of Common Stock2018-01-23T21:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that it plans to offer and sell, subject to market and other conditions, $75,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, Five Prime intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15% of these shares of common stock offered in the public offering.]]>https://www.globenewswire.com/news-release/2018/01/08/1285086/0/en/Five-Prime-Therapeutics-Earns-IND-Milestone-Payment-Under-Immune-Checkpoint-Pathways-Discovery-Collaboration-with-Bristol-Myers-Squibb-and-Announces-that-BMS-has-Extended-the-Resea.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time2018-01-08T13:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it has achieved a milestone for the first Investigational New Drug (IND) application to the U.S. Food and Drug Administration by Bristol-Myers Squibb Company (BMS) (NYSE:BMY) for a therapeutic candidate under the immune checkpoint pathway discovery collaboration between the companies. The first clinical candidate from the collaboration is a fully-human monoclonal antibody targeting TIM-3 (T-cell immunoglobulin and mucin domain-3), an immune checkpoint receptor that is known to limit the duration and magnitude of T-cell responses1. This first IND application triggers a $5 million milestone payment to Five Prime.]]>https://www.globenewswire.com/news-release/2018/01/03/1281855/0/en/Five-Prime-Therapeutics-to-Present-at-36th-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference2018-01-03T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 4:30 pm (PT).]]>https://www.globenewswire.com/news-release/2018/01/03/1281851/0/en/Five-Prime-Therapeutics-Submits-Investigational-New-Drug-Application-for-Novel-B7-H4-Antibody-FPA150.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA1502018-01-03T21:05:00Z<![CDATA[Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells]]>https://www.globenewswire.com/news-release/2018/01/02/1277263/0/en/Five-Prime-Therapeutics-Initiates-Patient-Dosing-in-Phase-1-Lead-In-to-Phase-3-Global-Registrational-Trial-of-FPA144-in-Front-Line-Advanced-Gastric-Cancer.html?f=22&fvtc=4&fvtv=11636Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer2018-01-02T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial (NCT03343301) of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.]]>